Miao Xu et al. Genome sequencing analysis identifies Epstein–Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nature Genetics, 2019, 51, 1131–1136.
 Shaodong Hong et al. The Genomic Landscape of Epstein-Barr virusassociated pulmonary lymphoepithelioma-like carcinoma. Nature Communication, 2019, Doi.org/10.1038/s41467-019-10902-w.
 Khanfir K, Guinebretiere J M, Vanel D, et al. Unusual problems in breast cancer and a rare lung cancer case: Case 2. Aggressive fibromatosis of the chest wall arising near a breast prosthesis[J]. Journal of Clinical Oncology, 2003, 21(11): 2216-2218.
 Fang W, Hong S, Chen N, et al. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival[J]. Oncotarget, 2015, 6(32): 33019-33032.
 Travis, W. D. et al. The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. 2015, 10, 1243–1260.
 Hayashi, T. et al. Cytopathologic features and differential diagnostic considerations of primary lymphoepithelioma-like carcinoma of the lung. Diagn. Cytopathol. 2012, 40, 820–825.
 Begin, L. R., Eskandari, J., Joncas, J. & Panasci, L. Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung. J. Surg. Oncol. 1987, 36, 280–283.
 Li Zhang et al. Gemcitabine plus cisplatinversus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngealcarcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016, 388,1883-1892.